569348-14-7 Usage
Uses
Used in Pharmaceutical Research and Development:
1-N-CBZ-NIPECOTAMIDE is used as a precursor in the synthesis of new antiepileptic drugs, leveraging its GABA uptake inhibitory properties to potentially manage seizures and other neurological conditions.
Used in Organic Synthesis:
1-N-CBZ-NIPECOTAMIDE is employed as a protected amine intermediate in organic synthesis, where the Cbz group serves to prevent unwanted side reactions, facilitating the creation of more complex organic molecules.
Used in Neuropharmacological Research:
1-N-CBZ-NIPECOTAMIDE is utilized as a research tool to study the GABA system, which is crucial for understanding the mechanisms of epilepsy and other related neurological disorders, thereby aiding in the development of more effective treatments.
Used in Drug Design:
1-N-CBZ-NIPECOTAMIDE is used as a structural template in drug design, with its unique properties guiding the creation of novel pharmaceuticals that can modulate the GABAergic system for therapeutic benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 569348-14-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,6,9,3,4 and 8 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 569348-14:
(8*5)+(7*6)+(6*9)+(5*3)+(4*4)+(3*8)+(2*1)+(1*4)=197
197 % 10 = 7
So 569348-14-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H18N2O3/c15-13(17)12-7-4-8-16(9-12)14(18)19-10-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2,(H2,15,17)
569348-14-7Relevant academic research and scientific papers
CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30
-
Page/Page column 48, (2018/04/17)
The present invention relates to a class of cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (I)
